Clinical Trial: Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer

U.S., Jan. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07339553) titled 'Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer' on Jan. 05.

Brief Summary: This study evaluates the efficacy and safety of Zeprumetostat in combination with Fuzuloparib for the treatment of patients with advanced or recurrent ovarian epithelial carcinoma, with the primary endpoint being Objective Response Rate (ORR).

Study Start Date: Jan. 04

Study Type: INTERVENTIONAL

Condition: Ovariancancer Platinum-sensitive Recurrent

Intervention: DRUG: Treatment

Phase 1: Fuzuloparib Monotherapy Dose: 150 mg, twice daily (bid), orally (po). Duration: Administr...